FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century

Huang, Rong; Pu, Yu; Huang, Shun; Yang, Chungang; Yang, Fake; Pu, Yongzhu; Li, Jindan; Chen, Long; Huang, Yunchao

doi:10.3389/fonc.2022.854658

Cited by 53 publications

(38 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies suggest that circulating FAP does not reflect expression levels in organ tissues ( 13 , 20 ). However, FAP can be used as a target structure by radiolabeled FAP-ligands for diagnostics by positron emission tomography in malignant tumors and myocardial injury ( 11 , 21 ). The reason for decreased FAP concentrations after stroke in our study remains unknown.…”

Section: Discussionmentioning

confidence: 99%

Circulating fibroblast activation protein α is reduced in acute ischemic stroke

Sieweke

Große

Weißenborn

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundFibroblast activation protein α (FAP), a membrane glycoprotein with dipeptidyl-peptidase and collagenase properties, is expressed in atherosclerotic plaques and remodeling of the extracellular matrix based on fibrosis. Fibrosis is a main contributor of atrial cardiomyopathies. In acute MI, circulating FAP is associated with outcome. Here, we investigated the correlation of circulating FAP to echocardiographic parameters of atrial remodeling and neurological impairment in acute ischemic stroke.MethodsCirculating FAP plasma concentrations were determined by ELISA in 47 patients with acute stroke and 22 control patients without stroke. Echocardiography was performed in all participants. Laboratory analysis, National Institutes of Health Stroke Scale (NIHSS) scoring and prolonged Holter-ECG-monitoring were performed in all stroke patients.ResultsPatients with acute stroke had lower circulating FAP concentrations than the control cohort (92 ± 24 vs. 106 ± 22 ng/mL, P < 0.001). There was no difference between the circulating FAP concentration comparing stroke due to atrial fibrillation, embolic stroke of undetermined source (ESUS) or atherosclerotic origin. Septal atrial conduction time (sPA-TDI) and left atrial (LA) volume index to tissue Doppler velocity (LAVI/a‘) representing echocardiographic parameters of LA remodeling did not correlate with FAP concentrations (sPA-TDI: r = 0.123, p = 0.31; LAVI/a‘: r = 0.183, p = 0.132). Stroke severity as assessed by NIHSS inversely correlated with circulating FAP (r = −0.318, p = 0.04). FAP concentration had a fair accuracy for identifying stroke in the receiver operating characteristic (ROC) analysis (AUC = 0.710, 95% CI: 0.577–0.843). A FAP concentration of 101 ng/mL discriminated between presence and absence of stroke with a sensitivity of 72% and a specificity of 77%. Lower circulating FAP concentration was associated with cardio-cerebro-vascular events within 12 months after admission.ConclusionsOur study is the first to associate FAP with echocardiographic parameters of LA-remodeling and function. FAP did not correlate with sPA-TDI and LAVI/a‘. However, FAP was associated with stroke, neurological impairment, and cardio-cerebral events within 12 months. Therefore, FAP might enable individualized risk stratification in ischemic stroke.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating fibroblast activation protein α is reduced in acute ischemic stroke

Sieweke

Große

Weißenborn

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…By using chelators to connect FAP inhibitors (FAPI) or FAP antibodies to radionuclides and then performing PET/CT imaging, PET/MR imaging or SPECT imaging, the imaging research of malignant tumors targeting FAP was carried out [ 16 , 17 , 18 ]. The imaging agent may be used to determine the clinical stages and monitor the recurrence of cancer and may be used as a biomarker or patient selection tool in clinical trials to predict clinical treatment response.…”

Section: Fibroblast Activation Protein (Fap) and Fapimentioning

confidence: 99%

FAPI PET/CT in Diagnostic and Treatment Management of Colorectal Cancer: Review of Current Research Status

Cheng

Wang

et al. 2023

JCM

View full text Add to dashboard Cite

FAPI PET/CT is a novel imaging tool targeting fibroblast activation protein (FAP), with high tumor uptake rate and low background noise. Therefore, the appearance of FAPI PET/CT provides a good tumor-to-background ratio between tumor and non-tumor tissues, which is beneficial to staging, tumor description and detection. Colorectal cancer has the biological characteristics of high expression of FAP, which provides the foundation for targeted FAP imaging. FAPI PET/CT may have a potential role in changing the staging and re-staging of colorectal cancer, monitoring recurrence and treatment management, and improving the prognosis of patients. This review will summarize the application status of FAPI PET/CT in colorectal cancer and provide directions for further application research.

show abstract

“…To our knowledge, no studies have been published to date to demonstrate the utility of FAPI PET/CT in paediatric oncology; however, recent research shows that FAPI is a promising tracer, which will demonstrate value in imaging multiple malignancies as prospective studies comparing FAPI with conventional FDG, DOTA-SSA and DOPA are currently enrolled [98].…”

Section: Future Perspectivesmentioning

confidence: 99%

The Impact of PET/CT on Paediatric Oncology

Brink

Hlongwa

2023

Diagnostics

View full text Add to dashboard Cite

This review paper will discuss the use of positron emission tomography/computed tomography (PET/CT) in paediatric oncology. Functional imaging with PET/CT has proven useful to guide treatment by accurately staging disease and limiting unnecessary treatments by determining the metabolic response to treatment. 18F-Fluorodeoxyglucose (2-[18F]FDG) PET/CT is routinely used in patients with lymphoma. We highlight specific considerations in the paediatric population with lymphoma. The strengths and weaknesses for PET/CT tracers that compliment Meta-[123I]iodobenzylguanidine ([123I]mIBG) for the imaging of neuroblastoma are summarized. 2‑[18F]FDG PET/CT has increasingly been used in the staging and evaluation of disease response in sarcomas. The current recommendations for the use of PET/CT in sarcomas are given and potential future developments and highlighted. 2-[18F]FDG PET/CT in combination with conventional imaging is currently the standard for disease evaluation in children with Langerhans-cell Histiocytosis (LCH) and the non-LCH disease spectrum. The common pitfalls of 2-[18F]FDG PET/CT in this setting are discussed.

show abstract

FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century

Cited by 53 publications

References 76 publications

Circulating fibroblast activation protein α is reduced in acute ischemic stroke

Circulating fibroblast activation protein α is reduced in acute ischemic stroke

FAPI PET/CT in Diagnostic and Treatment Management of Colorectal Cancer: Review of Current Research Status

The Impact of PET/CT on Paediatric Oncology

Contact Info

Product

Resources

About